Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses

Implications in gene therapy

Stanley Moffatt, John Hays, Harm HogenEsch, Suresh K. Mittal

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

To determine whether non-human adenovirus-specific antibodies are cross- neutralizing, rabbit and mouse anti-human adenovirus type 5 (HAd5), anti- bovine adenovirus type 3 (BAd3), and anti-porcine adenovirus type 3 (PAd3) sera were used in cross-virus neutralization assays. Adenovirus neutralizing antibodies were found to be virus-specific, suggesting that virus neutralizing epitope differs significantly in HAd5, BAd3, and PAd3. To further investigate whether immunity to an HAd5-derived vector could be circumvented by the use of non-human adenoviruses in vivo, mice were first immunized either intranasally or intraperitoneally with HAd5, BAd3, PAd3, or BAd3 + PAd3, and after development of adenovirus-specific antibodies, animals were inoculated with the HAd5 recombinant (AdCA36lacZ) containing the bacterial β-galactosidase gene under the control of murine cytomegalovirus immediate-early promoter. Virus-inoculated animals developed virus-specific IgG and IgA antibodies. LacZ expression in animals initially primed with HAd5 was significantly reduced (P < 0.05), suggesting that the immune response against the vector could prevent the transgene expression following subsequent inoculation of the same vector, whereas LacZ expression in mice initially primed with BAd3, PAd3, or BAd3 + PAd3 was significantly higher (P > 0.05) than that obtained in HAd5-primed animals. Our results suggest that HAd5-, BAd3-, or PAd3-based vectors may be used sequentially for human gene therapy or vaccine production as a means to avoid immunity to the vector. (C) 2000 Academic Press.

Original languageEnglish (US)
Pages (from-to)159-167
Number of pages9
JournalVirology
Volume272
Issue number1
DOIs
StatePublished - Jun 20 2000
Externally publishedYes

Fingerprint

Human Adenoviruses
Neutralizing Antibodies
Porcine Adenoviruses
Adenoviridae
Genetic Therapy
Antibody Formation
Viruses
Immunity
Galactosidases
Muromegalovirus
Bacterial Genes
Antibodies
Immunoglobulin A
Epitopes
Vaccines
Immunoglobulin G
Rabbits

Keywords

  • Bovine adenovirus
  • Gene therapy
  • Human adenovirus
  • Non-human adenovirus
  • Porcine adenovirus

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses : Implications in gene therapy. / Moffatt, Stanley; Hays, John; HogenEsch, Harm; Mittal, Suresh K.

In: Virology, Vol. 272, No. 1, 20.06.2000, p. 159-167.

Research output: Contribution to journalArticle

@article{99b86e4a12e9456682202b4457ac4440,
title = "Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: Implications in gene therapy",
abstract = "To determine whether non-human adenovirus-specific antibodies are cross- neutralizing, rabbit and mouse anti-human adenovirus type 5 (HAd5), anti- bovine adenovirus type 3 (BAd3), and anti-porcine adenovirus type 3 (PAd3) sera were used in cross-virus neutralization assays. Adenovirus neutralizing antibodies were found to be virus-specific, suggesting that virus neutralizing epitope differs significantly in HAd5, BAd3, and PAd3. To further investigate whether immunity to an HAd5-derived vector could be circumvented by the use of non-human adenoviruses in vivo, mice were first immunized either intranasally or intraperitoneally with HAd5, BAd3, PAd3, or BAd3 + PAd3, and after development of adenovirus-specific antibodies, animals were inoculated with the HAd5 recombinant (AdCA36lacZ) containing the bacterial β-galactosidase gene under the control of murine cytomegalovirus immediate-early promoter. Virus-inoculated animals developed virus-specific IgG and IgA antibodies. LacZ expression in animals initially primed with HAd5 was significantly reduced (P < 0.05), suggesting that the immune response against the vector could prevent the transgene expression following subsequent inoculation of the same vector, whereas LacZ expression in mice initially primed with BAd3, PAd3, or BAd3 + PAd3 was significantly higher (P > 0.05) than that obtained in HAd5-primed animals. Our results suggest that HAd5-, BAd3-, or PAd3-based vectors may be used sequentially for human gene therapy or vaccine production as a means to avoid immunity to the vector. (C) 2000 Academic Press.",
keywords = "Bovine adenovirus, Gene therapy, Human adenovirus, Non-human adenovirus, Porcine adenovirus",
author = "Stanley Moffatt and John Hays and Harm HogenEsch and Mittal, {Suresh K.}",
year = "2000",
month = "6",
day = "20",
doi = "10.1006/viro.2000.0350",
language = "English (US)",
volume = "272",
pages = "159--167",
journal = "Virology",
issn = "0042-6822",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses

T2 - Implications in gene therapy

AU - Moffatt, Stanley

AU - Hays, John

AU - HogenEsch, Harm

AU - Mittal, Suresh K.

PY - 2000/6/20

Y1 - 2000/6/20

N2 - To determine whether non-human adenovirus-specific antibodies are cross- neutralizing, rabbit and mouse anti-human adenovirus type 5 (HAd5), anti- bovine adenovirus type 3 (BAd3), and anti-porcine adenovirus type 3 (PAd3) sera were used in cross-virus neutralization assays. Adenovirus neutralizing antibodies were found to be virus-specific, suggesting that virus neutralizing epitope differs significantly in HAd5, BAd3, and PAd3. To further investigate whether immunity to an HAd5-derived vector could be circumvented by the use of non-human adenoviruses in vivo, mice were first immunized either intranasally or intraperitoneally with HAd5, BAd3, PAd3, or BAd3 + PAd3, and after development of adenovirus-specific antibodies, animals were inoculated with the HAd5 recombinant (AdCA36lacZ) containing the bacterial β-galactosidase gene under the control of murine cytomegalovirus immediate-early promoter. Virus-inoculated animals developed virus-specific IgG and IgA antibodies. LacZ expression in animals initially primed with HAd5 was significantly reduced (P < 0.05), suggesting that the immune response against the vector could prevent the transgene expression following subsequent inoculation of the same vector, whereas LacZ expression in mice initially primed with BAd3, PAd3, or BAd3 + PAd3 was significantly higher (P > 0.05) than that obtained in HAd5-primed animals. Our results suggest that HAd5-, BAd3-, or PAd3-based vectors may be used sequentially for human gene therapy or vaccine production as a means to avoid immunity to the vector. (C) 2000 Academic Press.

AB - To determine whether non-human adenovirus-specific antibodies are cross- neutralizing, rabbit and mouse anti-human adenovirus type 5 (HAd5), anti- bovine adenovirus type 3 (BAd3), and anti-porcine adenovirus type 3 (PAd3) sera were used in cross-virus neutralization assays. Adenovirus neutralizing antibodies were found to be virus-specific, suggesting that virus neutralizing epitope differs significantly in HAd5, BAd3, and PAd3. To further investigate whether immunity to an HAd5-derived vector could be circumvented by the use of non-human adenoviruses in vivo, mice were first immunized either intranasally or intraperitoneally with HAd5, BAd3, PAd3, or BAd3 + PAd3, and after development of adenovirus-specific antibodies, animals were inoculated with the HAd5 recombinant (AdCA36lacZ) containing the bacterial β-galactosidase gene under the control of murine cytomegalovirus immediate-early promoter. Virus-inoculated animals developed virus-specific IgG and IgA antibodies. LacZ expression in animals initially primed with HAd5 was significantly reduced (P < 0.05), suggesting that the immune response against the vector could prevent the transgene expression following subsequent inoculation of the same vector, whereas LacZ expression in mice initially primed with BAd3, PAd3, or BAd3 + PAd3 was significantly higher (P > 0.05) than that obtained in HAd5-primed animals. Our results suggest that HAd5-, BAd3-, or PAd3-based vectors may be used sequentially for human gene therapy or vaccine production as a means to avoid immunity to the vector. (C) 2000 Academic Press.

KW - Bovine adenovirus

KW - Gene therapy

KW - Human adenovirus

KW - Non-human adenovirus

KW - Porcine adenovirus

UR - http://www.scopus.com/inward/record.url?scp=0034691085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034691085&partnerID=8YFLogxK

U2 - 10.1006/viro.2000.0350

DO - 10.1006/viro.2000.0350

M3 - Article

VL - 272

SP - 159

EP - 167

JO - Virology

JF - Virology

SN - 0042-6822

IS - 1

ER -